Fortis Healthcare Board Approves Q3 FY26 Results and New ESOP Scheme
Fortis Healthcare's Board approved Q3 FY26 standalone and consolidated financial results. The company also approved the 'Fortis Healthcare Limited Employee Stock Option Scheme 2026' (ESOP 2026), which includes a pool of 1,50,99,163 stock options. The Board also approved revisions to the Related Party Transaction Policy.
The approval of financial results is routine, but the introduction of a new ESOP scheme can have a medium-term impact on employee morale and potential dilution. The revision of the RPT policy is also a governance positive.
The approval of financial results and the introduction of an ESOP scheme are generally positive developments for the company and its employees.
Fortis Healthcare Limited announced the outcome of its Board Meeting held on February 13, 2026. The Board approved the un-audited standalone and consolidated financial results for the quarter and period ended December 31, 2025. The accompanying Limited Review Report from the Statutory Auditor and a certificate regarding Financial Covenants were also approved and enclosed.
Additionally, the Board, based on the recommendation of the Nomination and Remuneration Committee, approved the formulation and implementation of the 'Fortis Healthcare Limited Employee Stock Option Scheme 2026' (ESOP 2026). This scheme is subject to shareholder approval and other necessary regulatory and statutory approvals. A pool of 1,50,99,163 employee stock options will be granted under ESOP 2026, each entitling the holder to one fully paid-up equity share of face value ₹10. The exercise price will be equal to the market price on the relevant date, not less than the face value. The exercise period for vested options is a maximum of four years from the vesting date.
The Board also approved revisions to the Related Party Transaction Policy. The Board Meeting commenced at 12:00 Hours (IST) and concluded at 18:40 Hours (IST).
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.